Phase II study of the amsacrine analogue CI-921 (NSC 343499) in non-small cell lung cancer.

Abstract

CI-921 (NSC 343499; 9-[[2-methoxy-4-[(methylsulphonyl)amino]phenyl]amino] -N,5-dimethyl- 4-acridinecarboxamide) is a topoisomerase II poison with high experimental antitumour activity. It was administered by 15 min infusion to 16 evaluable patients with non-small cell lung cancer (NSCLC) (7 with no prior treatment, 9 patients in relapse following surgery/radiotherapy) at a dose (648 mg/m2 divided over 3 days, repeated every 3 weeks) determined by phase I trial. Patients had a median performance status of 1 (WHO), and median age of 61 years. The histology comprised squamous carcinoma (11), adenocarcinoma (1), mixed histology (2), bronchio-alveolar carcinoma (1) and large cell undifferentiated carcinoma (1). Neutropenia grade greater than or equal to 3 was seen in 15 patients, infections with recovery in 3, and grand mal seizures in 1 patient. Grade less than or equal to 2 nausea and vomiting occurred in 66% courses and phlebitis in the infusion arm in 37%. 1 patient with squamous cell carcinoma achieved a partial response lasting 5 months. Further testing in this and other tumour types using multiple daily schedules is warranted.

• Authors: V J Harvey, J R Hardy, S Smith, W Grove, B C Baguley
• Journal: European journal of cancer (Oxford, England : 1990) (Eur J Cancer) Vol. 27 Issue 12 Pg. 1617-20 ( 1991) ISSN: 0959-8049 [Print] England
• PMID: 1664218 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)

Chemical References

• Antineoplastic Agents
• Amsacrine
• asulacrine

Topics

• Adult
• Aged
• Amsacrine (adverse effects, analogs & derivatives, therapeutic use)
• Antineoplastic Agents (therapeutic use)
• Carcinoma, Non-Small-Cell Lung (drug therapy)
• Drug Evaluation
• Female
• Humans
• Lung Neoplasms (drug therapy)
• Male
• Middle Aged
• Nausea (chemically induced)
• Neutropenia (chemically induced)
• Seizures (chemically induced)